Roll Call: Latest News on Capitol Hill, Congress, Politics and Elections
January 28, 2015

Posts in "Cancer"

January 28, 2015

Medicare Advisers to Focus on Cancer Tests

A panel of Medicare advisers will review evidence of how well certain tests work in helping doctors gauge the progress of lung, breast and colon cancer and what help these diagnostics can provide in choosing treatments.

A March 24 meeting of the Medicare Evidence Development and Coverage Advisory Committee has been scheduled to look at products that are meant to pick up on genetic variations produced in cancer cells.

Medicare is seeking the opinions of its advisers on about whether such tests can help patients live longer as a result of better treatment decisions and avoid complications from certain chemotherapies.

A report released last year raised questions about the ultimate benefits of some of the tests.

Doctors rely on the products in shaping discussions with patients about whether their prognosis is better or worse than average, according to the report from the Agency for Healthcare Research and Quality. Much of the available evidence focuses on determining prognosis, but there’s been little emphasis on how the information may affect the outcomes of treatment for patients, such as with the selection of medicines, the report stated.

“Such changes in management may be occurring and may be of benefit, or possibly harm, to patients, but they have not been measured and studied, with the notable exception of the Oncotype DX assay in breast cancer,” the authors wrote.

They added that there is “a sizeable body of evidence” to suggest Oncotype DX results in fewer recommendations for chemotherapy, and thus less exposure for some patients to the harms of this treatment, but noted that there are still questions about the effect on this test on outcomes for patients.

The deliberations of MedCAC panels are meant to aid the Centers for Medicare and Medicaid Services in setting payment policies, but are not binding. At the March meeting, the advisers’ discussion is intended to help CMS shape decisions “about the extent to which it may wish to use existing evidence as the basis for any future determinations about coverage for tests that estimate cancer prognosis.”

As part of the discussion, Medicare intends to have this expert panel weigh in on one of the liveliest current topics in the arena of diagnostics.

Among the questions to be considered by the panel is whether the regulatory status of a test should count in considering evidence of how it will work. The Food and Drug Administration last year kicked off what promises to be lengthy tussle with academic health centers and companies that make diagnostic products, by officially unveiling a new framework for regulating certain tests used in cutting-edge medicine.

The FDA is reconsidering what had long been a hands-off approach to lab-developed tests. Decades ago, lab-developed tests often were used by doctors and pathologists working in a single medical center. But advances in genetics have blurred the distinction between the lab-developed tests and other diagnostics. Many large companies now market medical tests nationwide and even globally without getting FDA clearance.

The Oncotype DX diagnostics from Genomic Health, for example, are considered lab-developed tests. Redwood City, California-based Genomic Health calls these a service, through which its laboratory provides through an analysis of the genes expressed in certain tumors. The company has agreements with distributors in more than 90 countries, and reported product revenue of $206.6 million for the nine months ended in September 2014.

By Kerry Young Posted at 10:30 a.m.
Cancer

July 31, 2014

Congress Presses FDA on Sunscreen; Surgeon General Warns on Skin Cancer

The House earlier this week quietly passed by voice vote a bill that would streamline the Food and Drug Administration application process for sunscreen ingredients. The measure sets a specific timetable to review applications.

Full story

July 29, 2014

Breast Cancer Awareness Has Bipartisan Appeal

It’s difficult to find common ground on many major legislative topics between Sen. Amy Klobuchar, D-Minn., and David Vitter, R-La., and Reps. Debbie Wasserman Schultz, D-Fl., and Renee Ellmers, R-N.C. However, health topics can be a unifying force in Congress.

Full story

By Paul Jenks Posted at 3:50 p.m.
Cancer

CDC Updates Stats on Low Teen Cancer Vaccination Rates

[field name=iframe]

The Centers for Disease Control and Prevention recently sounded an alarm with new statistics about the low rate of vaccination of teenagers against human papillomavirus. The health monitoring agency noted that teens are getting the HPV cancer vaccine at a lower rate than other vaccines.

Full story

July 22, 2014

Nuclear Agency Adjusts Radiation Treatment Rules

A variety of regulatory agencies supervise the delivery of health care. Perhaps the most overlooked agency is the Nuclear Regulatory Commission. The NRC is responsible for monitoring the safety in the use of radiation treatments using radioactive byproduct materials.

Full story

By Paul Jenks Posted at 8:59 a.m.
Cancer

July 21, 2014

New Bills: Contraceptive Services and Breast Cancer Detection

Last week’s Senate vote on a measure intended to roll back the Supreme Court’s Hobby Lobby decision prompted new legislation seeking to secure access to contraceptive services from New Jersey Democratic Sen. Cory Booker, plus a bill offered by Illinois Democrat Richard J. Durbin that would confirm recently announced Obama administration guidance on employee notification of omitted contraception coverage.

Full story

Sign In

Forgot password?

Or

Subscribe

Receive daily coverage of the people, politics and personality of Capitol Hill.

Subscription | Free Trial

Logging you in. One moment, please...